Skip to main content

Table 1 Basic characteristics of newly diagnosed AML patients with or without cardiac injury

From: Development of a risk assessment model for cardiac injury in patients newly diagnosed with acute myeloid leukemia based on a multicenter, real-world analysis in China

Characteristics

Total (n = 399)

No. (%) / Median (IQR)

Comparison

With cardiac injury (n = 161)

No. (%) / Median (IQR)

Without cardiac injury (n = 238)

No. (%) / Median (IQR)

 P

Gender

   

0.863

 Male

216(54.1)

88(54.7)

128(53.8)

 

 Female

183(45.9)

73(45.3)

110(46.2)

 

Age (years)

   

0.309

 Age < 60

218(54.6)

83(51.6)

135(56.7)

 

 Age ≥ 60

181(45.4)

78(48.4)

103(43.3)

 

Smoking history

67(16.8)

27(16.8)

40(16.8)

0.992

History of hypertension

67(16.8)

28(17.4)

39(16.4)

0.792

History of diabetes

29(7.3)

16(9.9)

13(5.5)

0.091

WBC (109/L)

10.14(2.2-37.13)

24.6(5.87–77.2)

5.27(1.72-15.0425)

< 0.001

RBC (1012/L)

2.19(1.7–2.62)

2.32(1.83–2.87)

2.12(1.65–2.56)

0.002

Hb (g/L)

70(56.4–85.8)

70(59.35–87.4)

69.55(54.6-84.85)

0.152

PLT (109/L)

38(21–73)

33(19-77.5)

39(21–73)

0.602

BM blast ratio (%)

59.5(35.5–80.5)

64(37-83.25)

57(33.375-76)

0.007

FAB subtypes

    

 M1

32(8)

7(4.3)

25(10.5)

0.026

 M2

176(44.1)

66(41.0)

110(46.2)

0.302

 M3

52(13)

19(11.8)

33(13.9)

0.548

 M4

22(5.5)

8(5.0)

14(5.9)

0.695

 M5

72(18)

40(24.8)

32(13.4)

0.004

 M6

5(1.3)

3(1.9)

2(0.8)

0.658

 Unkown

40(10)

18(11.2)

22(9.2)

0.527

Gene mutations

    

 NPM1

63(15.8)

42(26.1)

21(8.8)

< 0.001

 CEBPA

42(10.5)

17(10.6)

25(10.5)

0.986

 FLT3

67(16.8)

43(26.7)

24(10.1)

< 0.001

 C-kit

15(3.8)

9(5.6)

6(2.5)

0.114

 TP53

24(6.0)

12(7.5)

12(5.0)

0.320

 RUNX1

17(4.3)

7(4.3)

10(4.2)

0.943

 Ras

20(5.0)

13(8.1)

7(2.9)

0.021

 TET2

26(6.5)

14(8.7)

12(5.0)

0.147

 IDH

37(9.3)

18(11.2)

19(8.0)

0.280

 WT1

235(58.9)

109(67.7)

126(52.9)

0.003

 JAK2

11(2.8)

10(6.2)

1(0.4)

0.002#

 AML1-ETO

29(7.3)

14(8.7)

15(6.3)

0.366

 CBFB-MYH11

17(4.3)

6(3.7)

11(4.6)

0.664#

 BCR-ABL

14(3.5)

9(5.6)

5(2.1)

0.063#

 MLL

23(5.8)

8(5.0)

15(6.3)

0.575

Cytogenetics

    

 Abnormal karyotype

209(52.4)

92(57.1)

117(49.2)

0.117

 Complex karyotype

71(17.8)

26(16.1)

45(18.9)

0.480

 Monosomy karyotype

44(11.0)

16(9.9)

28(11.8)

0.568

 t8-21

23(5.8)

13(8.1)

10(4.2)

0.103

 inv16

15(3.8)

6(3.7)

9(3.8)

0.977#

 t9-22

5(1.3)

3(1.9)

2(0.8)

0.658#

 plus8

38(9.5)

16(9.9)

22(9.2)

0.817

 del5q

29(7.3)

14(8.7)

15(6.3)

0.366

 del7

25(6.3)

9(5.6)

16(6.7)

0.647

 del17p

14(3.5)

6(3.7)

8(3.4)

0.846#

Abnormal NT-proBNP

101(25.3)

58(36.0)

43(18.1)

< 0.001

Echocardiogram indexes

    

 LA (mm)

34(30–38)

34(31-37.5)

33(29.75-38)

0.357

 LV (mm)

45(42–48)

45(43–48)

46(42–48)

0.871

 IVS (mm)

10(9–11)

10(9–11)

10(9–11)

0.019

 EDV (ml)

97(78–113)

95(80-108.5)

97(78–118)

0.254

 ESV (ml)

31(25–40)

31(24–41)

30(25–39)

0.910

 SV (ml)

66(55–78)

64(53–75)

67(56–80)

0.172

 EF (%)

65(60–70)

64(60-70.5)

66(60–70)

0.062

  1. #: Fisher’s exact test
  2. NPM1: nucleophosmin 1; CEBPA: CCAAT/enhancer-binding protein alpha; FLT3: Fms-like tyrosine kinase 3; TP53, Tumor Protein P53; RUNX1: runt-related transcription factor 1; TET2: tet methylcytosine dioxygenase 2; IDH: Isocitrate dehydrogenase; WT1: Wilm tumor gene1; JAK2: Janus kinase 2; AML1-ETO: acute myeloid leukemia 1 Eight-twenty-one; CBFB-MYH11: core-binding factor, beta subunit-myosin heavy chain 11; BCR-ABL: breakpoint cluster region-Abelson; MLL: Mixed lineage leukemia; NT-pro BNP: N-terminal pro-B-type natriuretic peptide; WBC: White blood cells; RBC: Red blood cells; Hb: Hemoglobin; PLT: Platelets; LA: Left atrium; LV: Left ventricle; IVS: Interventricular septum; EDV: End-diastolic volume; ESV: End-systolic volume; SV: stroke volume; EF: Ejection fraction; BM: bone marrow
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us